Age and Risks of FDA-Approved Long-Acting β2-Adrenergic Receptor Agonists

AW McMahon, MS Levenson, BW McEvoy… - …, 2011 - publications.aap.org
OBJECTIVE: To determine the risk, by age group, of serious asthma-related events with long-
acting β2-adrenergic receptor agonists marketed in the United States for asthma …
被引用次数：109 相关文章

Age and Risks of FDA-Approved Long-Acting β2-Adrenergic Receptor Agonists

AW McMahon, MS Levenson, BW McEvoy… - Pediatrics, 2011 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> OBJECTIVE:</jats: title>< jats: p> To determine the risk, by age
group, of serious asthma-related events with long-acting β2-adrenergic receptor agonists …

Age and risks of FDA-approved long-acting β₂-adrenergic receptor agonists.

AW McMahon, MS Levenson, BW McEvoy… - Pediatrics, 2011 - europepmc.org
Objective To determine the risk, by age group, of serious asthma-related events with long-
acting β (2)-adrenergic receptor agonists marketed in the United States for asthma. Methods …

Age and risks of FDA-approved long-acting β₂-adrenergic receptor agonists

AW McMahon, MS Levenson, BW McEvoy… - …, 2011 - pubmed.ncbi.nlm.nih.gov
Objective To determine the risk, by age group, of serious asthma-related events with long-
acting β (2)-adrenergic receptor agonists marketed in the United States for asthma. Methods …

Age and risks of FDA-approved long-acting β2-adrenergic receptor agonists.

AW McMahon, MS Levenson, BW McEvoy… - 2011 - cabidigitallibrary.org
OBJECTIVE: To determine the risk, by age group, of serious asthma-related events with long-
acting β2-adrenergic receptor agonists marketed in the United States for asthma …